Global Direct-acting Antiviral Drugs Market Research Report 2022

Report Format: PDF   |   Report ID: 5515760   |   Published Date: August 2022   |   Pages:  91  

Choose License
Market Analysis and Insights: Global Direct-acting Antiviral Drugs Market
The global Direct-acting Antiviral Drugs market size is projected to reach US$  million by 2028, from US$  million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, NS3/4A Protease Inhibitors accounting for % of the Direct-acting Antiviral Drugs global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Direct-acting Antiviral Drugs market size is valued at US$  million in 2021, while the North America and Europe Direct-acting Antiviral Drugs are US$  million and US$  million, severally. The proportion of the North America is  % in 2021, while China and Europe are  % and respectively, and it is predicted that China proportion will reach  % in 2028, trailing a CAGR of  % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR  %,  %, and   % respectively for the next 6-year period. As for the Europe Direct-acting Antiviral Drugs landscape, Germany is projected to reach US$  million by 2028 trailing a CAGR of  % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Direct-acting Antiviral Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Direct-acting Antiviral Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Direct-acting Antiviral Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Direct-acting Antiviral Drugs market.
Global Direct-acting Antiviral Drugs Scope and Market Size
Direct-acting Antiviral Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Direct-acting Antiviral Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
    NS3/4A Protease Inhibitors
    Nucleoside and Nucleotide NS5B Polymerase Inhibitors
    NS5A Inhibitors
    Non-Nucleoside NS5B Polymerase Inhibitors
Segment by Application
    Hospitals
    Clinics
    Ambulatory Surgical Centers
    Pharmacies
    Others
By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA
By Company
    AbbVie Inc.
    GSK
    Boehringer Ingelheim
    Merck
    Novartis
    Beximco Pharmaceuticals
    Roche
    Bristol-Myers Squibb Company
    Gilead Sciences
    Janssen (Johnson & Johnson)
    Vertex Pharmaceuticals
    Natco Pharma
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 NS3/4A Protease Inhibitors
        1.2.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
        1.2.4 NS5A Inhibitors
        1.2.5 Non-Nucleoside NS5B Polymerase Inhibitors
    1.3 Market by Application
        1.3.1 Global Direct-acting Antiviral Drugs Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Ambulatory Surgical Centers
        1.3.5 Pharmacies
        1.3.6 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Direct-acting Antiviral Drugs Market Perspective (2017-2028)
    2.2 Direct-acting Antiviral Drugs Growth Trends by Region
        2.2.1 Direct-acting Antiviral Drugs Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Direct-acting Antiviral Drugs Historic Market Size by Region (2017-2022)
        2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Region (2023-2028)
    2.3 Direct-acting Antiviral Drugs Market Dynamics
        2.3.1 Direct-acting Antiviral Drugs Industry Trends
        2.3.2 Direct-acting Antiviral Drugs Market Drivers
        2.3.3 Direct-acting Antiviral Drugs Market Challenges
        2.3.4 Direct-acting Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Direct-acting Antiviral Drugs Players by Revenue
        3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2017-2022)
        3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2017-2022)
    3.2 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Direct-acting Antiviral Drugs Revenue
    3.4 Global Direct-acting Antiviral Drugs Market Concentration Ratio
        3.4.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2021
    3.5 Direct-acting Antiviral Drugs Key Players Head office and Area Served
    3.6 Key Players Direct-acting Antiviral Drugs Product Solution and Service
    3.7 Date of Enter into Direct-acting Antiviral Drugs Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Direct-acting Antiviral Drugs Breakdown Data by Type
    4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2017-2022)
    4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2023-2028)
5 Direct-acting Antiviral Drugs Breakdown Data by Application
    5.1 Global Direct-acting Antiviral Drugs Historic Market Size by Application (2017-2022)
    5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Direct-acting Antiviral Drugs Market Size (2017-2028)
    6.2 North America Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
    6.3 North America Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Direct-acting Antiviral Drugs Market Size (2017-2028)
    7.2 Europe Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
    7.3 Europe Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size (2017-2028)
    8.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
    8.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Direct-acting Antiviral Drugs Market Size (2017-2028)
    9.2 Latin America Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
    9.3 Latin America Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size (2017-2028)
    10.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
    10.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 AbbVie Inc.
        11.1.1 AbbVie Inc. Company Detail
        11.1.2 AbbVie Inc. Business Overview
        11.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction
        11.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.1.5 AbbVie Inc. Recent Development
    11.2 GSK
        11.2.1 GSK Company Detail
        11.2.2 GSK Business Overview
        11.2.3 GSK Direct-acting Antiviral Drugs Introduction
        11.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.2.5 GSK Recent Development
    11.3 Boehringer Ingelheim
        11.3.1 Boehringer Ingelheim Company Detail
        11.3.2 Boehringer Ingelheim Business Overview
        11.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction
        11.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.3.5 Boehringer Ingelheim Recent Development
    11.4 Merck
        11.4.1 Merck Company Detail
        11.4.2 Merck Business Overview
        11.4.3 Merck Direct-acting Antiviral Drugs Introduction
        11.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.4.5 Merck Recent Development
    11.5 Novartis
        11.5.1 Novartis Company Detail
        11.5.2 Novartis Business Overview
        11.5.3 Novartis Direct-acting Antiviral Drugs Introduction
        11.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.5.5 Novartis Recent Development
    11.6 Beximco Pharmaceuticals
        11.6.1 Beximco Pharmaceuticals Company Detail
        11.6.2 Beximco Pharmaceuticals Business Overview
        11.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction
        11.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.6.5 Beximco Pharmaceuticals Recent Development
    11.7 Roche
        11.7.1 Roche Company Detail
        11.7.2 Roche Business Overview
        11.7.3 Roche Direct-acting Antiviral Drugs Introduction
        11.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.7.5 Roche Recent Development
    11.8 Bristol-Myers Squibb Company
        11.8.1 Bristol-Myers Squibb Company Company Detail
        11.8.2 Bristol-Myers Squibb Company Business Overview
        11.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction
        11.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.8.5 Bristol-Myers Squibb Company Recent Development
    11.9 Gilead Sciences
        11.9.1 Gilead Sciences Company Detail
        11.9.2 Gilead Sciences Business Overview
        11.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction
        11.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.9.5 Gilead Sciences Recent Development
    11.10 Janssen (Johnson & Johnson)
        11.10.1 Janssen (Johnson & Johnson) Company Detail
        11.10.2 Janssen (Johnson & Johnson) Business Overview
        11.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction
        11.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.10.5 Janssen (Johnson & Johnson) Recent Development
    11.11 Vertex Pharmaceuticals
        11.11.1 Vertex Pharmaceuticals Company Detail
        11.11.2 Vertex Pharmaceuticals Business Overview
        11.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction
        11.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.11.5 Vertex Pharmaceuticals Recent Development
    11.12 Natco Pharma
        11.12.1 Natco Pharma Company Detail
        11.12.2 Natco Pharma Business Overview
        11.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction
        11.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
        11.12.5 Natco Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables Table 1. Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028 Table 2. Key Players of NS3/4A Protease Inhibitors Table 3. Key Players of Nucleoside and Nucleotide NS5B Polymerase Inhibitors Table 4. Key Players of NS5A Inhibitors Table 5. Key Players of Non-Nucleoside NS5B Polymerase Inhibitors Table 6. Global Direct-acting Antiviral Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Direct-acting Antiviral Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Direct-acting Antiviral Drugs Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Direct-acting Antiviral Drugs Market Share by Region (2017-2022) Table 10. Global Direct-acting Antiviral Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Direct-acting Antiviral Drugs Market Share by Region (2023-2028) Table 12. Direct-acting Antiviral Drugs Market Trends Table 13. Direct-acting Antiviral Drugs Market Drivers Table 14. Direct-acting Antiviral Drugs Market Challenges Table 15. Direct-acting Antiviral Drugs Market Restraints Table 16. Global Direct-acting Antiviral Drugs Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Direct-acting Antiviral Drugs Market Share by Players (2017-2022) Table 18. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2021) Table 19. Ranking of Global Top Direct-acting Antiviral Drugs Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Direct-acting Antiviral Drugs Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Direct-acting Antiviral Drugs Product Solution and Service Table 23. Date of Enter into Direct-acting Antiviral Drugs Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Direct-acting Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2017-2022) Table 27. Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2023-2028) Table 29. Global Direct-acting Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2017-2022) Table 31. Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Direct-acting Antiviral Drugs Revenue Market Share by Application (2023-2028) Table 33. North America Direct-acting Antiviral Drugs Market Size by Country (2017-2022) & (US$ Million) Table 34. North America Direct-acting Antiviral Drugs Market Size by Country (2023-2028) & (US$ Million) Table 35. Europe Direct-acting Antiviral Drugs Market Size by Country (2017-2022) & (US$ Million) Table 36. Europe Direct-acting Antiviral Drugs Market Size by Country (2023-2028) & (US$ Million) Table 37. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2017-2022) & (US$ Million) Table 38. Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2023-2028) & (US$ Million) Table 39. Latin America Direct-acting Antiviral Drugs Market Size by Country (2017-2022) & (US$ Million) Table 40. Latin America Direct-acting Antiviral Drugs Market Size by Country (2023-2028) & (US$ Million) Table 41. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2017-2022) & (US$ Million) Table 42. Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2023-2028) & (US$ Million) Table 43. AbbVie Inc. Company Detail Table 44. AbbVie Inc. Business Overview Table 45. AbbVie Inc. Direct-acting Antiviral Drugs Product Table 46. AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 47. AbbVie Inc. Recent Development Table 48. GSK Company Detail Table 49. GSK Business Overview Table 50. GSK Direct-acting Antiviral Drugs Product Table 51. GSK Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 52. GSK Recent Development Table 53. Boehringer Ingelheim Company Detail Table 54. Boehringer Ingelheim Business Overview Table 55. Boehringer Ingelheim Direct-acting Antiviral Drugs Product Table 56. Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 57. Boehringer Ingelheim Recent Development Table 58. Merck Company Detail Table 59. Merck Business Overview Table 60. Merck Direct-acting Antiviral Drugs Product Table 61. Merck Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 62. Merck Recent Development Table 63. Novartis Company Detail Table 64. Novartis Business Overview Table 65. Novartis Direct-acting Antiviral Drugs Product Table 66. Novartis Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 67. Novartis Recent Development Table 68. Beximco Pharmaceuticals Company Detail Table 69. Beximco Pharmaceuticals Business Overview Table 70. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product Table 71. Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 72. Beximco Pharmaceuticals Recent Development Table 73. Roche Company Detail Table 74. Roche Business Overview Table 75. Roche Direct-acting Antiviral Drugs Product Table 76. Roche Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 77. Roche Recent Development Table 78. Bristol-Myers Squibb Company Company Detail Table 79. Bristol-Myers Squibb Company Business Overview Table 80. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product Table 81. Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 82. Bristol-Myers Squibb Company Recent Development Table 83. Gilead Sciences Company Detail Table 84. Gilead Sciences Business Overview Table 85. Gilead Sciences Direct-acting Antiviral Drugs Product Table 86. Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 87. Gilead Sciences Recent Development Table 88. Janssen (Johnson & Johnson) Company Detail Table 89. Janssen (Johnson & Johnson) Business Overview Table 90. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product Table 91. Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 92. Janssen (Johnson & Johnson) Recent Development Table 93. Vertex Pharmaceuticals Company Detail Table 94. Vertex Pharmaceuticals Business Overview Table 95. Vertex Pharmaceuticals Direct-acting Antiviral DrugsProduct Table 96. Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 97. Vertex Pharmaceuticals Recent Development Table 98. Natco Pharma Company Detail Table 99. Natco Pharma Business Overview Table 100. Natco Pharma Direct-acting Antiviral DrugsProduct Table 101. Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million) Table 102. Natco Pharma Recent Development Table 103. Research Programs/Design for This Report Table 104. Key Data Information from Secondary Sources Table 105. Key Data Information from Primary Sources List of Figures Figure 1. Global Direct-acting Antiviral Drugs Market Share by Type: 2021 VS 2028 Figure 2. NS3/4A Protease Inhibitors Features Figure 3. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Features Figure 4. NS5A Inhibitors Features Figure 5. Non-Nucleoside NS5B Polymerase Inhibitors Features Figure 6. Global Direct-acting Antiviral Drugs Market Share by Application in 2021 & 2028 Figure 7. Hospitals Case Studies Figure 8. Clinics Case Studies Figure 9. Ambulatory Surgical Centers Case Studies Figure 10. Pharmacies Case Studies Figure 11. Others Case Studies Figure 12. Direct-acting Antiviral Drugs Report Years Considered Figure 13. Global Direct-acting Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 14. Global Direct-acting Antiviral Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 15. Global Direct-acting Antiviral Drugs Market Share by Region: 2021 VS 2028 Figure 16. Global Direct-acting Antiviral Drugs Market Share by Players in 2021 Figure 17. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2021) Figure 18. The Top 10 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2021 Figure 19. North America Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 20. North America Direct-acting Antiviral Drugs Market Share by Country (2017-2028) Figure 21. United States Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Canada Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 24. Europe Direct-acting Antiviral Drugs Market Share by Country (2017-2028) Figure 25. Germany Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 26. France Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 27. U.K. Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. Italy Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. Russia Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Nordic Countries Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Asia-Pacific Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Asia-Pacific Direct-acting Antiviral Drugs Market Share by Region (2017-2028) Figure 33. China Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 34. Japan Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 35. South Korea Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 36. Southeast Asia Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 37. India Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Australia Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. Latin America Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Latin America Direct-acting Antiviral Drugs Market Share by Country (2017-2028) Figure 41. Mexico Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Brazil Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 43. Middle East & Africa Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 44. Middle East & Africa Direct-acting Antiviral Drugs Market Share by Country (2017-2028) Figure 45. Turkey Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 46. Saudi Arabia Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 47. AbbVie Inc. Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 48. GSK Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 49. Boehringer Ingelheim Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 50. Merck Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 51. Novartis Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 52. Beximco Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 53. Roche Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 54. Bristol-Myers Squibb Company Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 55. Gilead Sciences Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 56. Janssen (Johnson & Johnson) Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 57. Vertex Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 58. Natco Pharma Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022) Figure 59. Bottom-up and Top-down Approaches for This Report Figure 60. Data Triangulation Figure 61. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us